Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 22, 2017

View Archived Issues

CCAT1 and CCAT2 long noncoding RNAs as novel prognostic biomarkers in colorectal cancer

Novel role of APLNR gene in regulating the response to cancer immunotherapy

TFAM overexpression rescues sperm defects in infertile mtDNA mutator mice

Effective in vivo Mnk1/2 inhibitors identified for blast crisis chronic myelogenous leukemia

Amgen's cyclopropyloxazines, a new series of BACE1 inhibitors for Alzheimer's disease

FDA approves Duzallo to treat hyperuricemia associated with gout

Samsung Bioepis and Takeda begin strategic biologic codevelopment collaboration

Alkermes begins rolling NDA submission for ALKS-5461 as adjuvant treatment of MDD

Chiesi discovers new phosphatidylinositol 3-kinase inhibitors

Novel 5-HT-2 receptor antagonists patented by Shenzhen Targetrx Biotechnology

Jiangsu Chia Tai Tianqing, Centaurus BioPharma and Lianyungang Ruzhong present new BET inhibitors

FDA grants orphan drug designation to SY-1425 for AML

European Commission approves new indication for Soliris in refractory generalized myasthenia gravis

Ilkos Therapeutic initiates phase II study of S-42909 for leg ulcer healing

Trovagene's PCM-075 shows synergy with HDAC inhibitor in NHL cell lines

BioLineRx files regulatory submissions to begin phase III study of BL-8040 in stem cell mobilization

FDA advises on Cardiome's planned NDA resubmission for Brinavess

Patient enrollment under way in first-in-human trial of M-8891

Mavyret now available in U.S. for chronic HCV

Dr. Reddy's reports out-licensing of DFD-06 to Encore Dermatology

Sorrento announces contribution to formation of Celularity

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.